Hearing loss tobramycin

Ototoxicity with both auditory and vestibulatory effects is the most serious of the adverse reactions of aminogycosides as it is mostly irreversible. Vestibular involvement manifests itself by dizziness, nystagmus, vertigo and ataxia. Cochlear toxicity results initially in high-frequency hearing loss. Amikacin more often causes cochlear damage than vestibular problems, while gentamicin and tobramycin are associated more frequently with vestibular symptoms. 

The renal toxicity of cisplatin is potentiated by aminoglycoside antibacterials such as gentamicin and tobramycin. Extra care is required in patients treated with cisplatin requiring these antibacterials. In one retrospective analysis in patients taking cisplatin, hearing loss was not associated with the concurrent use of ototoxic drugs, including tobramycin. 

---